ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)?-Reference-Cited by-同舟云学术

ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)?

Published:2024-05-09 Issue:7 Volume:31 Page:4702-4703
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Yamada Daisaku,Kobayashi Shogo,Takahashi Hidenori,Iwagami Yoshifumi,Akita Hirofumi,Asukai Kei,Shimizu Junzo,Yamada Terumasa,Tanemura Masahiro,Yokoyama Shigekazu,Tsujie Masanori,Asaoka Tadafumi,Takeda Yutaka,Morimoto Osakuni,Tomokuni Akira,Doki Yuichiro,Eguchi Hidetoshi

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1245/s10434-024-15244-6.pdf

Reference5 articles.

1. Seufferlein T, Uhl W, Kornmann M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2023;34(1):91–100.

2. Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch Randomized Phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73.

3. Unno M, Motoi F, Matsuyama Y, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). J Clin Oncol 2019;37(15suppl):4126.

4. Sohal D, Duong MT, Ahmad SA, et al. SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). J Clin Oncol. 2020;38(15suppl):4504.

5. Daisaku Y, Shogo K, Hidenori T, et al. Results of a randomized clinical study of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (RCT, CSGO-HBP-015). Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15199-8.